Latest News

"A 30% discrepancy in results." During his talk at EACVI, Professor James Moon shared the moment he realised the tools doctors relied on simply weren't good enough. For a clinician dealing with heart failure, that ambiguity was unacceptable. This is the story of how a concern for "metrology", the science of measurement, turned into a mission to exceed human performance. From scanning patients o....

We are delighted to announce a major strategic partnership between MyCardium AI and Optum | Change Healthcare Enterprise Imaging Healthcare, one of the largest and most trusted enterprise imaging and PACS integration providers in the world. This collaboration represents a significant milestone for MyCardium AI and marks the beginning of a new era in cardiovascular imaging, where intelligent a....

MyCardium AI has been recognised among the UK’s top 16 AI startups to watch, following its inclusion in Sifted’s latest feature highlighting ventures shaping the future of artificial intelligence across multiple industries. The article, based on insights from leading venture capital firms including Amadeus Capital Partners, Baltic Ventures, Ada Ventures and others, identifies emerging....

London, UK - October 2025 MyCardium AI is proud to announce its role as the Core Laboratory in the recently published NEJM study: Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction. The trial investigated whether percutaneous coronary intervention (PCI) of nonculprit lesions should be performed immediately or deferred in patients with myocardial infarction. This study has signi....

MyCardium AI has been featured in the Financial Times article, “AI start-ups make big gains in healthcare.” The feature highlights a new generation of innovators using artificial intelligence to accelerate clinical decision-making and improve patient outcomes across global healthcare systems. As a spin-out from University College London (UCL), one of the world’s leading centres ....

EchoConfidence Receives FDA 510(k) Clearance We’re thrilled to share a major milestone at MyCardium AI, our AI-powered echocardiography platform, EchoConfidence, has officially received FDA 510(k) clearance! This clearance not only confirms the safety and effectiveness of EchoConfidence, but it also paves the way for the platform’s clinical use in the United States, bringing explai....

We were proud to sponsor this year’s British Cardiovascular Society (BCS) Annual Conference, where clinical education and cutting-edge technology came together to shape the future of cardiac imaging. As part of our commitment to advancing cardiovascular care, we showcased 1CMR Pro, our AI-powered cardiac MRI analysis solution, through an expertly delivered hands-on educational program. A Te....

Liverpool, UK – MyCardium AI, a pioneering Healthtech company developing cutting edge AI solutions for cardiac imaging, is proud to announce that it is now an official member of AXREM, the UK trade association representing the medical imaging and radiotherapy industry. By joining AXREM, MyCardium AI reinforces its commitment to collaboration, standards, and innovation within the UK ....

We are proud to announce that EchoConfidence has officially received CE Class IIb certification. A major milestone that reflects our unwavering commitment to safety, quality, and innovation in healthcare technology. What does Class IIb mean? This classification is reserved for medium-to-high-risk medical devices and indicates rigorous regulatory scrutiny. CE Class IIb approval confirms that 1E....

We’re thrilled to announce that our cutting-edge 1CMR Pro AI software has officially received CE Class IIb approval! This certification is a significant milestone, reinforcing our commitment to providing innovative, regulatory-approved AI solutions that enhance cardiovascular diagnostics. With CE Class IIb approval, MyCardium AI can now bring 1CMR Pro to more clinicians across Europe, help....

Prof. Charlotte Manisty joins The HealthTech Podcast to discuss the transformative role of AI in cardiac imaging. In this episode, she explores how AI-driven technologies like MyCardium AI are enhancing clinical workflows, improving diagnostics, and shaping the future of cardiovascular healthcare.

MyCardium AI can announce a significant milestone in cardiology innovation with the publication of cutting-edge research in the Journal of the American College of Cardiology (JACC). This study, led by Hunain Shiwani and supported by the expertise of Rhodri Davies from UCL, highlights the transformative potential of artificial intelligence in redefining how hypertrophic cardiomyopathy (HCM) is diag....

MyCardium AI, a leading innovator in cardiovascular imaging technology, is delighted to announce that its revolutionary AI-driven post processing analysis software for CMR (1CMR Pro) has received FDA 510(K) clearance. This significant milestone enables clinical use of the software in the US. The FDA's approval underscores the efficacy and safety of MyCardium AI's software in a clinical environmen....

We are proud to announce that MyCardium AI has officially received ISO 13485 accreditation, a prestigious certification that reflects our commitment to providing safe, effective, and high-quality AI-driven medical solutions. This certification marks a pivotal step in our journey toward reshaping the future of cardiovascular diagnostics, solidifying our place as a leader in the development of AI te....

A new guide designed to accelerate and support a new generation of innovative software spinouts has been launched by a leading group of universities, including UCL, with the advice and backing of major investors. Spinouts are companies usually formed by academics or researchers based on the intellectual property or research they developed at a university. The University Spinout Investment Term....

Cardiac MRI has helped hundreds of thousands of people with heart problems over the last 40 years. Dr Phoebe Kitscha learns more from three British Heart Foundation-funded scientists who are making progress in this area. Magnetic resonance imaging (MRI) is a type of medical scan first developed in the late 1980s. It uses a magnetic field and computer-generated radio waves to create detailed image....

Total Commitment to Data Security and Confidentiality MyCardium AI Ltd, a developer of innovative AI enhanced Cardiac Image Analysis tools and Cardiac Image Core Lab service company, is pleased to announce that it has been awarded ISO 27001 certification by BSI. This achievement underscores the company's unwavering commitment to safeguarding data privacy and security and to maintaining the highes....

The SCMR Technologist Award recognizes technologists who have made exemplary contributions to the Society and/or field of CMR. Candidates for this award should demonstrate a track record of distinguished service to the Society in the area of technologist education, training, practice development, mentoring, or research. Technologists can be nominated for this award by other SCMR members or the Aw....

Dr Rhodri Davies – UCL and Barts Heart Centre. Artificial intelligence is fuelling a new era of medicine. Dr Rhodri Davies has developed a new AI tool to detect heart disease in MRI images at record speed. This technology will support doctors in their ability to more accurately diagnose and treat patients, while saving precious clinician time. Source: Vote for your favourite BHF-funded rese....

Although a relatively young company, MyCardium’s specialization in advanced AI-enhanced analysis of cardiac images has already brought it to the attention of some of the world’s leading developers of new treatments for cardiac diseases and conditions. MyCardium’s Core Lab Services combine internationally recognized expertise with the enhanced accuracy, precision and consistency, ....

On Friday 10th February, MyCardium AI was delighted to receive the Liverpool City Region 'Official Tech Climber 2023' award, an award that recognises positive representation for the city of Liverpool in the technology sector from innovative and growing organisations. At a packed meeting held at the Love Lane Brewery in Liverpool, Chief Commercial Officer and Co-Founder of MyCardium AI Antony Shim....

Data security and data protection are both critical to MyCardium, and as a company we are committed to the very highest standards possible. We are pleased to announce completion of the NHS Data Security & Protection Toolkit by MyCardium staff. MyCardium’s regulatory lead, Michael Walker stated: MyCardium is committed to meeting the National Data Guardian’s (NDG) Data Security an....

The BRITISH Study (led by Dr Andrew Flett of University Hospitals Southampton) has recently been awarded £1.8m from the BHF. The study aims to determine whether heart muscle scar predicts high risk in dilated cardiomyopathy and therefore the use of implantable cardioverter defibrillators (ICD). The trial (1252 patients, 35 UK centres) will analyse Cardiac MRI scans and randomize those with s....